Test Price
2,800 AED✅ Home Collection Available
EYA4 Gene (DFNA10) Autosomal Dominant Hearing Loss Genetic Test (NGS) in UAE | 2,800 AED | 2026 DHA Guidelines
تحليل جين EYA4 للصمم الوراثي السائد الجسدي النوع 10 في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 15189 Accredited Next‑Generation Sequencing.
- Premium Logistics: Hospital‑Grade Home Blood Collection (8 AM–11 PM) using validated cold‑chain transport.
- Clinical Guidance: Telephonic post‑test result interpretation by a DHA‑licensed genetic counsellor.
- Insurance: Direct Billing Verification – WhatsApp +971 54 548 8731.
يقدم هذا الفحص الجيني دقة تفوق 99.9% وفق نظام الجودة الآيزو، مع خدمة سحب منزلي آمنة واستشارة وراثية بعد النتيجة، بما يتوافق مع توجيهات هيئة الصحة بدبي.
Overview
The EYA4 Gene Autosomal Dominant Hearing Loss Genetic Test uses Next‑Generation Sequencing to identify pathogenic variants in the EYA4 gene (DFNA10 locus), confirming hereditary, progressive sensorineural hearing loss. This test is indicated when clinical audiometry reveals post‑lingual, bilateral hearing impairment and a positive family history, providing a definitive molecular diagnosis to guide auditory rehabilitation and family planning.
| Parameter | Our Test – NGS (Full Gene) | Alternative – Targeted PCR Panel |
|---|---|---|
| Methodology | Next‑Generation Sequencing (Illumina) + bioinformatics | PCR‑based analysis of known hotspot mutations only |
| Variant Detection | All exons, splice sites – novel & known variants | Limited to pre‑selected point mutations |
| Analytical Sensitivity | >99.9% for single‑nucleotide variants | ~95% for targeted regions |
| Turnaround Time | 3–4 weeks | 4–6 weeks (may require reflex NGS) |
| UAE Regulatory Compliance | DHA‑licensed facility (License 9834453), ISO 9001:2015 Certified | Often outsourced without local quality oversight |
Physician Insight & Safety Protocol
Genetic testing for EYA4‑related autosomal dominant deafness provides a definitive molecular diagnosis, but must always be correlated with audiological findings and family history. A negative result does not rule out other genetic or acquired causes. If you have been prescribed hearing aids or any medication, do not discontinue them without consulting your doctor – discuss your results with your ENT specialist to adjust treatment safely.
Dr. PRABHAKAR REDDY, DHA License 61713011: “When a family carries the burden of progressive hearing loss, a precise genetic answer often brings emotional relief and practical direction. I always ensure that my patients understand that this test is a piece of the clinical puzzle, not a standalone verdict, and that a careful, compassionate interpretation makes all the difference.”
Clinical Safety & Exclusion Criteria
- Individuals unable to provide informed consent or without a legal guardian (minors must follow CDS Law 2026).
- Severe, uncontrolled bleeding diathesis; ensure coagulation profile is normal before blood draw.
- Acute psychiatric distress that may compromise understanding of genetic information.
- Pregnancy is not a contraindication; however, post‑partum sample collection is preferred for comfort.
Emergency Red Flags: Seek immediate medical attention if you experience sudden, profound hearing loss with vertigo, facial weakness, or severe tinnitus – do not rely on genetic testing for acute crises.
Pre‑test Requirements & Medication Note
A mandatory genetic counselling session is required to draw a three‑generation pedigree, explain autosomal dominant inheritance, and obtain documented informed consent per DHA standards. No dietary or medication adjustments are needed; however, if you are on anticoagulants, please inform the phlebotomist to ensure a safe blood draw. Sample types accepted: Whole blood (EDTA), dried blood spot on FTA card, or extracted DNA (shipped at ambient temperature).
Patient FAQ & Clinical Guidance
What is the EYA4 gene test and who should consider it?
This next‑generation sequencing analysis detects pathogenic variants in the EYA4 gene causing autosomal dominant nonsyndromic sensorineural hearing loss, recommended for individuals with progressive post‑lingual hearing deterioration and a family history of similar deafness.
يفحص هذا التحليل الجيني طفرات جين EYA4 المسببة للصمم الحسي العصبي الوراثي السائد، ويُنصح به لمن يعانون من ضعف سمع تدريجي بعد اكتساب اللغة مع تاريخ عائلي إيجابي.
How long until I receive my results and what is the cost?
Turnaround time is 3 to 4 weeks for the comprehensive NGS report, priced at 2,800 AED inclusive of home blood collection, genetic counselling, and telephonic post‑test result interpretation.
مدة إصدار التقرير من 3 إلى 4 أسابيع بتكلفة 2800 درهم إماراتي تشمل السحب المنزلي والاستشارة الوراثية قبل وبعد التحليل.
Is this genetic covered by UAE health insurance?
Many UAE insurers approve medically indicated EYA4 testing when accompanied by an ENT or geneticist referral; we provide direct billing verification via secure WhatsApp at +971 54 548 8731.
تغطي العديد من شركات التأمين في الإمارات هذا الفحص عند وجود إحالة طبية من أخصائي الأنف والأذن والحنجرة أو طبيب الوراثة، مع خدمة تحقق فوري عبر الواتساب.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians